
William Oliver Tobin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6291321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 441-452.	1.4	8
2	Populationâ€based incidence and clinicoâ€radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 2022, 29, 782-789.	1.7	11
3	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€mutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
4	Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist, 2022, 27, 144-148.	1.9	3
5	Inherited genetics of adult diffuse glioma and polygenic risk scores—a review. Neuro-Oncology Practice, 2022, 9, 259-270.	1.0	3
6	The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions. Multiple Sclerosis Journal, 2022, 28, 1710-1718.	1.4	1
7	Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer Journal, 2022, 12, .	2.8	3
8	Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology, 2021, 96, e1590-e1592.	1.5	1
9	Cyclophosphamide in treatment of tumefactive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102627.	0.9	10
10	Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-analysis. Evidence-Based Mental Health, 2021, 24, 88-94.	2.2	10
11	Singleâ€agent cladribine as an effective frontâ€line therapy for adults with Langerhans cell histiocytosis. American Journal of Hematology, 2021, 96, E146-E150.	2.0	21
12	Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7049-7049.	0.8	0
13	<i>BRAF</i> ^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis Journal of Clinical Oncology, 2021, 39, 7050-7050.	0.8	0
14	Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model. Radiology, 2021, 299, 313-323.	3.6	46
15	Clinical and Radiologic Features, Pathology, and Treatment of BalÃ ³ Concentric Sclerosis. Neurology, 2021, 97, e414-e422.	1.5	12
16	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	4.5	124
17	<scp>Magnetic Resonance Imaging</scp> Correlates of Multiple Sclerosis Immunopathological Patterns. Annals of Neurology, 2021, 90, 440-454.	2.8	12
18	Harry Lee Parker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 701-719.	1.2	0

#	Article	IF	CITATIONS
19	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Neurology, 2021, 97, e1906-e1913.	1.5	18
20	Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. American Journal of Hematology, 2021, 96, 1604-1610.	2.0	18
21	Early Diagnosis and Treatment Are Associated With Improved Outcomes in Patients With Multiple Sclerosis. Neurology, 2021, 97, 799-800.	1.5	3
22	Efficacy of Cobimetinib in Rosai-Dorfman Disease. Blood, 2021, 138, 1506-1506.	0.6	1
23	Classical and Non-Classical Phenotypes of Erdheim-Chester Disease: Correlating Clinical, Radiographic, and Genotypic Findings. Blood, 2021, 138, 2566-2566.	0.6	Ο
24	Mimics of Erdheimâ \in "Chester disease. British Journal of Haematology, 2021, , .	1.2	3
25	Pathological findings in central nervous system demyelination associated with infliximab. Multiple Sclerosis Journal, 2020, 26, 1124-1129.	1.4	11
26	Efficacy of BRAF-Inhibitor Therapy in <i>BRAF V600E</i> -Mutated Adult Langerhans Cell Histiocytosis. Oncologist, 2020, 25, 1001-1004.	1.9	25
27	Low-dose vemurafenib monotherapy in <i>BRAF^{V600E}</i> -mutated Erdheim-Chester disease. Leukemia and Lymphoma, 2020, 61, 2733-2737.	0.6	9
28	Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis. Aging, 2020, 12, 15134-15156.	1.4	8
29	Hirayama Disease Presenting as 4-Limb Paresthesia. Neurologist, 2020, 25, 187-189.	0.4	2
30	Reply to: "Crowell et al. Idiopathic Central Nervous System Inflammatory Disease in the Setting of HLA-B27 Uveitis― Ocular Immunology and Inflammation, 2019, 27, 918-919.	1.0	0
31	The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clinic Proceedings, 2019, 94, 2054-2071.	1.4	116
32	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood, 2019, 133, 1607-1610.	0.6	23
33	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1021-1026.	0.9	49
34	Growing the phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) in children. Developmental Medicine and Child Neurology, 2019, 61, 391-392.	1.1	3
35	Reply: CLIPPERS, a possible symptomatic lymphohistiocytic immune reaction. Brain, 2018, 141, e6-e6.	3.7	0
36	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology, 2018, 136, 419.	1.4	104

WILLIAM OLIVER TOBIN

#	Article	IF	CITATIONS
37	Clinical Reasoning: A 30-year-old man with headache and sleep disturbance. Neurology, 2018, 90, e1535-e1540.	1.5	4
38	Neuroradiologic manifestations of Erdheim-Chester disease. Neurology: Clinical Practice, 2018, 8, 15-20.	0.8	43
39	Reply: A case of CLIPPERS challenging the new diagnostic criteria. Brain, 2018, 141, e13-e13.	3.7	1
40	Facial Myokymia and Hemifacial Spasm in Multiple Sclerosis. Neurologist, 2018, 23, 1-6.	0.4	17
41	Neuromyelitis Optica and Herpes Simplex Virus 2. Neurologist, 2018, 23, 92-93.	0.4	8
42	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	2.5	108
43	Efficacy of biological agents in the treatment of Erdheimâ€Chester disease. British Journal of Haematology, 2018, 183, 520-524.	1.2	24
44	Population-based study of "no evident disease activity―in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e495.	3.1	6
45	Reply: Two cases of CLIPPERS with increased number of perivascular CD20-positive B lymphocytes. Brain, 2018, 141, e76-e76.	3.7	1
46	Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	1.7	295
47	Teaching Neurolmages: Optic nerve sheath meningioma presenting as gaze-evoked amaurosis. Neurology, 2018, 90, e2095-e2096.	1.5	4
48	Extracranial and Intracranial Vasculopathy With "Moyamoya Phenomenon―in Association With Alagille Syndrome. Frontiers in Neurology, 2018, 9, 1194.	1.1	9
49	Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing. Blood, 2018, 132, 1112-1112.	0.6	1
50	Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes. Journal of the Neurological Sciences, 2017, 375, 404-410.	0.3	9
51	Assessment of â€~on-treatment platelet reactivity' and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis. Journal of the Neurological Sciences, 2017, 376, 133-139.	0.3	8
52	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2017, 140, 2415-2425.	3.7	158
53	CLIPPERS. Current Neurology and Neuroscience Reports, 2017, 17, 65.	2.0	30
54	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – NO. Multiple Sclerosis Journal, 2017, 23, 1190-1192.	1.4	9

WILLIAM OLIVER TOBIN

#	Article	IF	CITATIONS
55	Clinical–radiological–pathological spectrum of central nervous system–idiopathic inflammatory demyelinating disease in the elderly. Multiple Sclerosis Journal, 2017, 23, 1204-1213.	1.4	6
56	Multiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings. Multiple Sclerosis Journal, 2016, 22, 698-704.	1.4	17
57	Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis. Multiple Sclerosis Journal, 2016, 22, 986-992.	1.4	44
58	The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology, 2016, 87, 1393-1399.	1.5	230
59	Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment. Journal of the Neurological Sciences, 2016, 361, 13-18.	0.3	16
60	Rituximab Therapy in Neuromyelitis Optica. JAMA Neurology, 2015, 72, 974.	4.5	3
61	Stopping immunomodulatory medications in MS: Frequency, reasons and consequences. Multiple Sclerosis and Related Disorders, 2015, 4, 437-443.	0.9	19
62	Teaching Neuro <i>Images</i> : Primary Sjögren syndrome presenting as isolated lesion of medulla oblongata. Neurology, 2015, 85, 204-205.	1.5	1
63	Cervical Artery Dissection in Young Adults in the Stroke in Young Fabry Patients (sifap1) Study. Cerebrovascular Diseases, 2015, 39, 110-121.	0.8	17
64	Diagnostic Yield and Safety of Cerebellar and Brainstem Parenchymal Biopsy. World Neurosurgery, 2015, 84, 1973-1976.	0.7	12
65	Sexual dimorphism in clinical neurology—predictors of successful lumbar puncture in an "expanding―population. Obesity, 2014, 22, 1747-1749.	1.5	0
66	Longitudinally extensive transverse myelitis. Current Opinion in Neurology, 2014, 27, 279-289.	1.8	56
67	DPPX potassium channel antibody. Neurology, 2014, 83, 1797-1803.	1.5	255
68	Frequent inaccuracies in ABCD2 scoring in non-stroke specialists' referrals to a daily Rapid Access Stroke Prevention service. Journal of the Neurological Sciences, 2013, 332, 30-34.	0.3	18
69	Prevalence of ExÂVivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100® and VerifyNow®. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e84-e92.	0.7	24
70	173â€Footfalls echo in the memory. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.130-e1.	0.9	0
71	Enhanced <i>ex vivo</i> inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: First results from the TRinity AntiPlatelet responsiveness (TrAP) study. British Journal of Haematology, 2011, 152, 640-647.	1.2	21
72	Interobserver agreement in ABCD scoring between non-stroke specialists and vascular neurologists following suspected TIA is only fair. Journal of Neurology, 2011, 258, 1001-1007.	1.8	9

#	Article	IF	CITATIONS
73	Immediate Effects of Thermal–Tactile Stimulation on Timing of Swallow in Idiopathic Parkinson's Disease. Dysphagia, 2010, 25, 207-215.	1.0	63
74	Dual origin of the left vertebral artery: Extracranial MRA and CTA findings. Journal of the Neurological Sciences, 2010, 298, 150-152.	0.3	4
75	Identification of Stroke Mimics in the Emergency Department Setting. Journal of Brain Disease, 2009, 1, JCNSD.S2280.	0.1	25
76	Stroke and newspapers: inattention or neglect?. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 259-261.	0.7	3
77	Left atrial appendage occlusion in non-valvular atrial fibrillation. Lancet, The, 2009, 374, 504-506.	6.3	4
78	Herpes zoster in the T1 dermatome presenting with Horner's syndrome, radicular weakness, and postherpetic neuralgia. International Medical Case Reports Journal, 2008, 1, 1.	0.3	2